Radiation Dermatitis
Conditions
Keywords
Radiation dermatitis
Brief summary
Radiation-induced dermatitis is the most common complication of radiotherapy for cancer treatment. However, there is no satisfactory management to deal with the problem. Ru-Yi-Jin-Huang Powder is one of most common topical TCM drug to treat skin diseases but lack of evidence to support efficacy. The aim of this trial is to evaluate the effectiveness of Ru-Yi-Jin-Huang Powder for radiation-induced dermatitis.
Detailed description
The common management of head and neck cancer are concurrent chemoradiotherapy (CCRT) after surgical section. Radiation-induced dermatitis is the most common complication of radiotherapy for cancer, affecting approximately 95 percent of patients receiving radiotherapy. The skin changes include erythema, edema, pigment changes, hair loss, and dry or moist desquamation. It may cause xerostomia, hard food taking, severe infection to delay the completion of course of treatment. Although, there are lots of topical drug to deal with radiation dermatitis, there is no best way to manage the skin problems. Ru-Yi-Jin-Huang Powder is one of most common topical TCM drug to treat skin ulcer, joint swelling or other infective or inflammatory diseases. Some study showed that Ru-Yi-Jin-Huang Powder can be used to decrease edema or swelling, pain relief, decrease phlebitis or mumps. However, there is no related evidence to support Ru-Yi-Jin-Huang Powder for radiation dermatitis. Thus, the aim of the study is to evaluate the effectiveness of Ru-Yi-Jin-Huang Powder for radiation-induced dermatitis.
Interventions
DRUGRu-Yi-Jin-Huang Powder
Ru-Yi-Jin-Huang Powder is the most common TCM topical drug for skin diseases. It is often used to treat skin ulcers, sprain of joint with swelling, and other inflammatory diseases.
Sponsors
Chang Gung Memorial Hospital
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* stage 3 or 4 of head and neck cancer or nasopharyngeal cancer with pathological confirmed malignancy undergoing concurrent chemoradiotherapy more than 20 times or radiation dermatitis \> CTCAE grade 2. * more than 18 years old. * VAS score \> 6 with poor response to narcotics. * estimated survival time of \> 6 months. * be suitable for TCM topical treatment after evaluation by TCM physicians. * willingness to joint this trial and sign consent form of study.
Exclusion criteria
* non-head and neck cancer or have not receive CCRT. * not be suitable for Ru-Yi-Jin-Huang topical treatment after TCM physicians evaluation. * history of allergy to TCM topical use. * poor conscious to answer questionnaires. * pregnancy. * KPS \< 30.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change of VAS score from baseline and 2 months | VAS score is assessed by physicians 2 times a week, up to 8 weeks. | The Visual Analogue Scale (VAS) consists of a straight line with the endpoints defining extreme limits such as 0 of 'no pain at all' and 10 of 'pain as bad as it could be'. |
| Change of CTCAE version 4 from baseline and 2 months | CTCAE is assessed by physicians once a week with photos following, up to 8 weeks. | The criteria is used for the management of chemoradiotherapy administration. and dosing, and to provide standardization and consistency in the definition of treatment-related toxicity. |
| Change of Skindex-16 from baseline and 2 months | Skindex-16 is assessed by physicians once a week, up to 8 weeks. | The scale is a brief quality-of-life measure for patients with skin diseases. |
Contacts
Primary ContactZi-Yu Chang
Outcome results
None listed